Tirzepatide – 60mg/vial (Research Use Only)

Overview

Tirzepatide is a synthetic dual-agonist peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its dual-receptor mechanism provides a pharmacological tool for studying complementary incretin signaling pathways simultaneously, and it has been extensively examined in published preclinical and clinical pharmacology literature focused on metabolic, cardiovascular, and hepatic biology.

What It Is

Tirzepatide is a 39-amino acid synthetic peptide designed as a dual agonist at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). It is based on the native GIP sequence with modifications enabling GLP-1 receptor co-activation and a C20 fatty diacid chain at lysine-26 for extended half-life via albumin binding. Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈. Molecular weight: approximately 4,813.45 Da. CAS number: 2023788-19-2.

Research Spotlight

The research profile of tirzepatide is defined by its dual-receptor mechanism, which activates both the GIP and GLP-1 pathways — systems with distinct but overlapping roles in postprandial glucose regulation, insulin secretion, glucagon suppression, and energy homeostasis. Published preclinical research has investigated tirzepatide’s differential effects on adipose tissue (GIP receptor-mediated) versus appetite and gastric motility (GLP-1 receptor-mediated), providing mechanistic data for comparative metabolic studies. Cardiovascular research has examined lipid profiles, myocardial inflammation markers, and vascular remodeling parameters in animal models. Comparative pharmacology studies have evaluated tirzepatide against semaglutide and other GLP-1 agonists to quantify receptor binding affinity and tissue-specific signaling differences. Additional published research has explored renal and hepatic biomarker responses in NASH and kidney function models, as well as skeletal muscle protein synthesis pathways in relevant animal preparations.

Key Research Applications

• Dual GIP and GLP-1 receptor co-activation and downstream signaling studies
• Comparative receptor pharmacology vs. GLP-1 mono-agonist compounds
• Pancreatic beta-cell insulin secretion and glucose-dependent insulinotropic modeling
• Adipose tissue biology, lipolysis, and body composition research
• Appetite, satiety signaling, and central GLP-1 pathway investigations
• Cardiovascular risk marker modulation and cardiac inflammation research
• NASH, hepatic steatosis, and renal function marker studies
• Skeletal muscle protein synthesis and lean mass preservation modeling
• Long-acting fatty acid-conjugated peptide pharmacokinetics
• Incretin receptor selectivity and synergy research

For laboratory research use only. Not intended for human or veterinary use, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.

Not sure which compounds fit your research? Browse the Research Hub →

Related Research (Educational)

• Body Recomposition with GLP-1 Peptides: What the Research Shows
• Muscle Preservation During Caloric Restriction: Research Compound Insights
• Visceral Fat and Metabolic Health: What Researchers Are Studying